Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma.
CTLA-4
PD-1
PD-L1
VEGFR-1
immune checkpoint
immune escape
macrophages
melanoma
metastasis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Nov 2020
17 Nov 2020
Historique:
received:
17
09
2020
revised:
03
11
2020
accepted:
13
11
2020
entrez:
20
11
2020
pubmed:
21
11
2020
medline:
21
11
2020
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) represent a promising therapeutic intervention for a variety of advanced/metastatic solid tumors, including melanoma, but in a large number of cases, patients fail to establish a sustained anti-tumor immunity and to achieve a long-lasting clinical benefit. Cells of the tumor micro-environment such as tumor-associated M2 macrophages (M2-TAMs) have been reported to limit the efficacy of immunotherapy, promoting tumor immune evasion and progression. Thus, strategies targeting M2-TAMs have been suggested to synergize with immune checkpoint blockade. This review recapitulates the molecular mechanisms by which M2-TAMs promote cancer immune evasion, with focus on the potential cross-talk between pharmacological interventions targeting M2-TAMs and ICIs for melanoma treatment.
Identifiants
pubmed: 33212945
pii: cancers12113401
doi: 10.3390/cancers12113401
pmc: PMC7698460
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG 2017-ID. 20353 project
Organisme : Italian Ministry of Health
ID : RC18-2638151
Références
Clin Exp Immunol. 2020 May;200(2):120-130
pubmed: 31930484
Cells. 2019 Dec 23;9(1):
pubmed: 31878087
Oncoimmunology. 2015 Oct 29;5(4):e1101204
pubmed: 27141383
Cell Rep. 2015 Oct 13;13(2):412-24
pubmed: 26411680
Immunotherapy. 2017 Oct;9(13):1103-1113
pubmed: 29032737
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
J Biomed Sci. 2019 Oct 20;26(1):78
pubmed: 31629410
J Pharmacol Exp Ther. 2018 Jan;364(1):77-86
pubmed: 29025978
Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14978-83
pubmed: 19706447
Clin Lab Med. 2017 Sep;37(3):449-471
pubmed: 28802495
Cell. 2016 Oct 20;167(3):829-842.e13
pubmed: 27745970
Immunol Rev. 2017 Mar;276(1):52-65
pubmed: 28258699
Melanoma Manag. 2019 Oct 18;6(3):MMT27
pubmed: 31807278
Eur J Cancer. 2006 Apr;42(6):717-27
pubmed: 16520032
Cancer Res. 2014 Sep 15;74(18):5057-69
pubmed: 25082815
Lancet Oncol. 2017 Sep;18(9):1202-1210
pubmed: 28729151
Nat Rev Immunol. 2005 Aug;5(8):641-54
pubmed: 16056256
JAMA. 2014 Nov 5;312(17):1744-53
pubmed: 25369488
Immunity. 2005 May;22(5):633-42
pubmed: 15894280
Immunity. 2014 Jul 17;41(1):21-35
pubmed: 25035951
J Invest Dermatol. 2020 Jul;140(7):1390-1400.e4
pubmed: 31945344
Surg Clin North Am. 2020 Feb;100(1):1-12
pubmed: 31753105
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32269145
Clin Cancer Res. 2021 Jan 1;27(1):202-212
pubmed: 33020056
J Thorac Oncol. 2012 Jul;7(7):1091-100
pubmed: 22534817
Blood. 2010 Sep 2;116(9):1454-9
pubmed: 20498301
Chemotherapy. 2019;64(2):62-80
pubmed: 31387102
Nat Immunol. 2018 Dec;19(12):1319-1329
pubmed: 30397348
Nature. 2016 Nov 17;539(7629):443-447
pubmed: 27828943
J Clin Oncol. 2009 Jul 10;27(20):3330-7
pubmed: 19528371
Nature. 2014 Sep 25;513(7519):559-63
pubmed: 25043024
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
J Clin Med. 2020 Jan 14;9(1):
pubmed: 31947592
Front Immunol. 2020 Feb 05;11:120
pubmed: 32117271
Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):16971-16980
pubmed: 31375632
Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):E4041-E4050
pubmed: 29632196
Comp Immunol Microbiol Infect Dis. 2019 Apr;63:22-30
pubmed: 30961814
J Leukoc Biol. 2010 Dec;88(6):1201-5
pubmed: 20807704
J Drug Target. 2019 Mar;27(3):244-256
pubmed: 29448849
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
J Hematol Oncol. 2018 Feb 27;11(1):31
pubmed: 29482595
Cancer Cell. 2013 Mar 18;23(3):277-86
pubmed: 23518347
FEBS J. 2018 Feb;285(4):700-716
pubmed: 29055087
Cell Metab. 2016 Nov 8;24(5):657-671
pubmed: 27641098
J Invest Dermatol. 2000 Dec;115(6):1000-7
pubmed: 11121133
J Exp Med. 2005 Oct 3;202(7):919-29
pubmed: 16186184
Nat Commun. 2020 Jan 23;11(1):437
pubmed: 31974367
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
Int J Mol Sci. 2020 Aug 27;21(17):
pubmed: 32867025
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Front Oncol. 2020 Jan 24;9:1512
pubmed: 32039007
Pharmacol Res. 2012 Jan;65(1):9-22
pubmed: 21930211
Melanoma Res. 2019 Oct;29(5):501-509
pubmed: 30575644
J Exp Med. 2016 Oct 17;213(11):2315-2331
pubmed: 27697834
Front Immunol. 2014 Oct 27;5:532
pubmed: 25386178
Trends Immunol. 2013 Nov;34(11):556-63
pubmed: 23954143
Nat Med. 2013 Oct;19(10):1264-72
pubmed: 24056773
Mod Pathol. 2017 Dec;30(12):1666-1676
pubmed: 28776578
Semin Immunopathol. 2013 Mar;35(2):123-37
pubmed: 22996682
PLoS One. 2013;8(2):e56045
pubmed: 23409120
PLoS One. 2014 Jun 03;9(6):e98623
pubmed: 24892425
Ann Oncol. 2019 Dec 1;30(12):1884-1901
pubmed: 31566661
Am J Cancer Res. 2016 Nov 01;6(11):2514-2531
pubmed: 27904768
Lancet Oncol. 2019 Aug;20(8):1083-1097
pubmed: 31221619
J Pathol. 2012 May;227(1):17-28
pubmed: 22262122
Nat Rev Immunol. 2011 Oct 14;11(11):723-37
pubmed: 21997792
Cell Mol Life Sci. 2016 Jul;73(13):2411-24
pubmed: 26956893
Invest Ophthalmol Vis Sci. 2011 Feb 03;52(2):643-50
pubmed: 20811059
Curr Opin Pharmacol. 2015 Aug;23:45-51
pubmed: 26051995
Front Immunol. 2015 Jan 12;5:673
pubmed: 25628622
J Immunol. 2006 Jun 1;176(11):6752-61
pubmed: 16709834
Int J Mol Sci. 2020 Mar 30;21(7):
pubmed: 32235439
Front Immunol. 2019 Nov 19;10:2641
pubmed: 31803182
Nat Med. 2017 May;23(5):551-555
pubmed: 28346412
Pigment Cell Melanoma Res. 2017 Jul;30(4):428-435
pubmed: 28379630
J Cell Physiol. 2018 Sep;233(9):6425-6440
pubmed: 29319160
J Exp Med. 2019 Oct 7;216(10):2394-2411
pubmed: 31375534
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Cells. 2019 Jul 19;8(7):
pubmed: 31331034
Pharmacol Res. 2018 Oct;136:97-107
pubmed: 30170190
Oncotarget. 2016 Nov 8;7(45):72868-72885
pubmed: 27655684
Front Oncol. 2020 Feb 25;10:188
pubmed: 32161718
Nat Med. 2019 Mar;25(3):454-461
pubmed: 30804515
Front Immunol. 2017 Aug 25;8:1024
pubmed: 28970830
Immunity. 2019 Jul 16;51(1):15-26
pubmed: 31315033
Nat Med. 2018 Nov;24(11):1649-1654
pubmed: 30297909
Immunity. 2017 Aug 15;47(2):284-297.e5
pubmed: 28813659
Nature. 2011 Jun 08;475(7355):222-5
pubmed: 21654748
Front Cell Dev Biol. 2018 Apr 04;6:38
pubmed: 29670880
Int J Mol Sci. 2020 Feb 18;21(4):
pubmed: 32085654
Cancer Res. 2018 Aug 1;78(15):4253-4269
pubmed: 29789416
Life Sci. 2019 May 1;224:222-231
pubmed: 30928403
Nat Cell Biol. 2016 May;18(5):549-60
pubmed: 27088855
J Hematol Oncol. 2019 Jul 12;12(1):76
pubmed: 31300030
Pharmacol Res. 2020 Sep;159:104957
pubmed: 32485280
Int J Oncol. 2016 Apr;48(4):1581-9
pubmed: 26846845
EBioMedicine. 2016 Apr;6:50-58
pubmed: 27211548
Inflamm Regen. 2018 Mar 5;38:3
pubmed: 29515691
Cancer Immunol Immunother. 2020 Nov;69(11):2319-2331
pubmed: 32507967
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2645-50
pubmed: 12598651
Mol Aspects Med. 2011 Apr;32(2):123-45
pubmed: 21565215
J Thorac Dis. 2018 Feb;10(Suppl 3):S480-S489
pubmed: 29593893
Acta Pharm Sin B. 2020 Nov;10(11):2156-2170
pubmed: 33304783
Sci Transl Med. 2017 May 10;9(389):
pubmed: 28490665
J Immunother Cancer. 2017 Dec 19;5(1):101
pubmed: 29254508
Adv Med Sci. 2019 Mar;64(1):104-110
pubmed: 30605863
J Immunol. 1991 Jan 1;146(1):108-13
pubmed: 1845802
Cancer Res. 2014 Apr 1;74(7):1933-44
pubmed: 24691994
Cancer Cell. 2014 Nov 10;26(5):623-37
pubmed: 25446896
Trends Mol Med. 2018 May;24(5):472-489
pubmed: 29655673
Cancer Immunol Immunother. 2018 Jul;67(7):1113-1121
pubmed: 29737375
Immunity. 2018 Feb 20;48(2):299-312.e5
pubmed: 29396160
Antioxid Redox Signal. 2013 Jun 10;18(17):2352-63
pubmed: 22900885
Sci Signal. 2016 Feb 16;9(415):ra19
pubmed: 26884601
Immunity. 2014 Nov 20;41(5):815-29
pubmed: 25453823
J Immunol. 2007 Jul 1;179(1):607-15
pubmed: 17579082
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643229
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
Immunity. 2018 Apr 17;48(4):773-786.e5
pubmed: 29625896
Oncoimmunology. 2020 Feb 17;9(1):1708065
pubmed: 32117584
Lancet Oncol. 2018 May;19(5):672-681
pubmed: 29602646
Mol Immunol. 2010 Feb;47(5):1083-90
pubmed: 20004021
Nat Biomed Eng. 2018 Aug;2(8):578-588
pubmed: 31015631
Cancers (Basel). 2019 Dec 30;12(1):
pubmed: 31905918
Cell Immunol. 2014 May-Jun;289(1-2):42-8
pubmed: 24721110
Crit Rev Oncol Hematol. 2017 Jul;115:36-49
pubmed: 28602168
Immunity. 2019 Apr 16;50(4):871-891
pubmed: 30995504
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
Am J Transl Res. 2019 Sep 15;11(9):6040-6054
pubmed: 31632572
Immunol Rev. 2017 Mar;276(1):66-79
pubmed: 28258694
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830
J Exp Med. 2006 Apr 17;203(4):871-81
pubmed: 16606666
Front Immunol. 2020 May 15;11:938
pubmed: 32499785